Parallel Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Parallel Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51K	Buy	+191	New	+$1.22K	﹤0.01%	3591
2025 Q1	–	Sell	-3,294	Closed	-$11.2K	–	3687
2024 Q4	$11.2K	Hold	3,294	–	–	﹤0.01%	2377
2024 Q3	$9.39K	Hold	3,294	–	–	﹤0.01%	2415
2024 Q2	$7.41K	Hold	3,294	–	–	﹤0.01%	2415
2024 Q1	$7.28K	Hold	3,294	–	–	﹤0.01%	2426
2023 Q4	$7.74K	Hold	3,294	–	–	﹤0.01%	2380
2023 Q3	$6.13K	Hold	3,294	–	–	﹤0.01%	2432
2023 Q2	$8.63K	Hold	3,294	–	–	﹤0.01%	2233
2023 Q1	$5.37K	Hold	3,294	–	–	﹤0.01%	2387
2022 Q4	$4.38K	Sell	3,294 -3,906	-54%	-$5.51K	﹤0.01%	2389
2022 Q3	$11K	Hold	7,200	–	–	﹤0.01%	1977
2022 Q2	$11K	Hold	7,200	–	–	﹤0.01%	1951
2022 Q1	$19K	Hold	7,200	–	–	﹤0.01%	1761
2021 Q4	$21K	Hold	7,200	–	–	﹤0.01%	1766
2021 Q3	$18K	Hold	7,200	–	–	﹤0.01%	1808
2021 Q2	$29K	Hold	7,200	–	–	﹤0.01%	1499
2021 Q1	$32K	Hold	7,200	–	–	﹤0.01%	1384
2020 Q4	$35K	Hold	7,200	–	–	﹤0.01%	1246
2020 Q3	$43K	Hold	7,200	–	–	﹤0.01%	1123
2020 Q2	$19K	Buy	+7,200	New	+$25.1K	﹤0.01%	1444

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Parallel Advisors's XERS Position: Q2 2026 in Review

Parallel Advisors opened a new position in Xeris Biopharma Holdings (XERS) in Q2 2026: 191 shares worth $1.51K. The stake represents ﹤0.01% of the portfolio and ranks #3591 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in XERS as recently as Q4 2024.

Parallel Advisors first reported a position in XERS in Q2 2020 and has held it in 20 quarters since. The position peaked at $43K in Q3 2020. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Parallel Advisors held 191 shares of Xeris Biopharma Holdings worth $1.51K as of Q2 2026.
Xeris Biopharma Holdings was a new Parallel Advisors position in Q2 2026.
Xeris Biopharma Holdings made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3591 holding.
Parallel Advisors first reported a position in Xeris Biopharma Holdings in Q2 2020 and has held it in 20 quarters since.
Parallel Advisors's Xeris Biopharma Holdings position peaked at $43K in Q3 2020.
240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.